Even after successful treatment, patients with Cushing's disease who were older when diagnosed or had prolonged exposure to excess cortisol face a greater risk of dying or developing cardiovascular disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
[More]
Repeat doses of corticosteroids may protect patients undergoing bilateral total knee arthroplasty from postoperative side effects such as fever, pain, and acute respiratory distress, research suggests.
[More]
The effects of using face paints for Halloween can be scary, says Sofia Chaudhry, M.D., assistant professor of dermatology at Saint Louis University.
[More]
Groundbreaking research into rare neonatal diseases, conducted by the University of Sheffield, is set to improve the treatment of babies who lack the stress hormone cortisol.
[More]
Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.
[More]
Cognition psychologists at the Ruhr-Universit-t together with colleagues from the University Hospital Bergmannsheil (Prof. Dr. Martin Tegenthoff) have discovered why stressed persons are more likely to lapse back into habits than to behave goal-directed. The team of PD Dr. Lars Schwabe and Prof. Dr. Oliver Wolf from the Institute for Cognitive Neuroscience have mimicked a stress situation in the body using drugs.
[More]
With the start of summer comes the appearance of common stinging insects, such as bees, wasps, hornets and yellowjackets, and the various related health risks that range from irritating but relatively harmless stings to the threat of serious allergic reaction. The National Pest Management Association (NPMA) stresses that when it comes to stinging insects, the best way to avoid the associated health risks is to practice simple prevention and treatment tips.
[More]
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.
[More]
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
[More]
Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.
[More]
CutisPharma, Inc. announced the introduction of FIRST - Mouthwash BLM 4oz and FIRST - Mouthwash BLM 6oz compounding kits. These products expand the FIRST Magic Mouthwash line for CutisPharma.
[More]
Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.
[More]
The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
[More]
A Wayne State University researcher is using a three-year, $1.55 million grant from the National Institute on Drug Abuse of the National Institutes of Health to learn more about the links between stress and drug use by applying behavioral economics.
[More]
Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.
[More]
People who suffer headaches after a spinal tap might have a relatively simple way to ease the painful throb: a caffeine tablet.
[More]
While the image of a bug crawling on your arm or a creepy crawler snuggling up in your bed is enough to make you flinch, most bug bites are harmless and disappear on their own in a matter of days. Other insects, however, can spread disease and cause severe reactions that require medical attention.
[More]
Family vacations live in infamy. Sometimes it's for the lasting memories of family bonding and new wonders experienced together, and sometimes for the horrors of just trying to get to a destination.
[More]
Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.
[More]
Meda and Valeant have entered into a collaboration agreement. Meda has out-licensed exclusive rights for Elidel and Xerese to Valeant for the U.S., Canada and Mexico. The parties will collaborate on life cycle opportunities for both products.
[More]